The abstract is read at the publisher; the summary is JClub's.
FDA postmarket surveillance systems are being evaluated for their use and sufficiency in further assessing serious risks identified at drug and biologic approval between 2016 and 2025.
- Why it matters: Approval-identified serious risks require follow-up after marketing, but it is unclear how well FDA surveillance systems are used and whether they are sufficient for that purpose.
- What they did: In a cross-sectional analysis, the study examined FDA postmarket surveillance systems to assess how they are used and whether they provide adequate coverage for serious risks found at approval from 2016–2025.
- The result: The evaluation clarifies the extent to which these surveillance systems can support further assessment of serious risks, informing how regulators may strengthen postmarket risk monitoring.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.